Nifty 17196.7 (-1.18%)
Sensex 57696.46 (-1.31%)
Nifty Bank 36197.15 (-0.85%)
Nifty IT 35848.05 (-0.86%)
Nifty Financial Services 17779.5 (-1.13%)
Adani Ports 737.45 (-0.22%)
Asian Paints 3110.45 (-2.21%)
Axis Bank 673.00 (-0.46%)
B P C L 385.90 (1.86%)
Bajaj Auto 3287.85 (-1.22%)
Bajaj Finance 7069.25 (-1.55%)
Bajaj Finserv 17488.70 (-1.52%)
Bharti Airtel 718.35 (-1.94%)
Britannia Inds. 3552.00 (-0.74%)
Cipla 912.05 (-1.00%)
Coal India 159.75 (0.28%)
Divis Lab. 4757.05 (-0.42%)
Dr Reddys Labs 4596.50 (-1.42%)
Eicher Motors 2455.55 (0.16%)
Grasim Inds 1703.90 (-1.16%)
H D F C 2771.65 (-1.29%)
HCL Technologies 1171.40 (-1.12%)
HDFC Bank 1513.55 (-0.80%)
HDFC Life Insur. 690.95 (-2.03%)
Hero Motocorp 2462.45 (-0.41%)
Hind. Unilever 2343.65 (-1.66%)
Hindalco Inds. 424.65 (-1.72%)
I O C L 122.20 (1.28%)
ICICI Bank 716.30 (-0.84%)
IndusInd Bank 951.15 (0.59%)
Infosys 1735.55 (-0.73%)
ITC 221.65 (-1.69%)
JSW Steel 644.55 (-0.34%)
Kotak Mah. Bank 1914.20 (-2.55%)
Larsen & Toubro 1801.25 (0.67%)
M & M 836.95 (-1.48%)
Maruti Suzuki 7208.70 (-1.59%)
Nestle India 19321.35 (-0.93%)
NTPC 127.00 (-1.32%)
O N G C 145.90 (1.32%)
Power Grid Corpn 206.10 (-3.92%)
Reliance Industr 2408.25 (-3.00%)
SBI Life Insuran 1165.95 (-1.86%)
Shree Cement 25914.05 (-1.43%)
St Bk of India 473.15 (-0.81%)
Sun Pharma.Inds. 751.80 (-1.89%)
Tata Consumer 774.30 (0.14%)
Tata Motors 480.10 (0.21%)
Tata Steel 1118.00 (0.50%)
TCS 3640.45 (-0.07%)
Tech Mahindra 1593.30 (-2.23%)
Titan Company 2369.25 (-0.72%)
UltraTech Cem. 7332.45 (0.13%)
UPL 712.75 (2.08%)
Wipro 640.75 (-0.94%)
INFY

Lupin Ltd.

₹873.
Not a customer?

Open free demat account
& trade instantly

Investment Ratings

As per analysts rating in the last 6 months, the recommendation is to HOLD Lupin

  • Master Rating:
  • Lupin (Nse) has an operating revenue of Rs. 16,161.98 Cr. on a trailing 12-month basis. An annual revenue de-growth of -4% needs improvement, Pre-tax margin of 11% is healthy, ROE of 8% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 30 which is a POOR score indicating inconsistency in earnings, a RS Rating of 8 which is FAIR indicating the recent price performance, Buyer Demand at D- which indicates heavy supply, Group Rank of 149 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Lupin Ltd Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Ratings

Eps And Sales Estimates

Lupin Ltd Synopsis

NSE-Medical-Generic Drugs

Lupin Ltd. is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 11055.93 Cr. and Equity Capital is Rs. 90.74 Cr. for the Year ended 31/03/2021. Lupin Ltd. is a Public Limited Listed company incorporated on 01/03/1983 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24100MH1983PLC029442 and registration number is 029442.
  • Market Cap

    INR 39,719.43 Cr

  • Sales

    INR 11,502.72 Cr

  • Shares in Float

    24.07 Cr

  • No of Funds

    594 K

  • Yield

    0.74%

  • Book Value

    2.14

  • U/D Vol Ratio

    1.1

  • LTDebt/Equity

    %

  • Alpha

    -0.1

  • Beta

    0.73

Lupin Ltd Ownership
Lupin Ltd Management

Lupin Ltd Financials

INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Total ShareHolders Funds Annual Cr 18565.5217473.1217117.2715784.9614780.24
Fixed Assets Annual Cr 4589.694335.884572.044511.73493.28
Total Non Current Assets Annual Cr 12241.199841.9910205.79963.558597.47
Total Current Assets Annual Cr 9617.3710838.519484.518717.459250.77
Total Assets Annual Cr 21858.5620680.519690.211868117848.24
INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Book Value Per Share Annual Rs 409.2024385.72378.2822349.1474327.286
ROE Annual % 6.774.168.988.5121.25
ROCE Annual % 8.6610.2815.3611.1727.53
Total Debt to Total Equity Annual -----
EBDIT Annual Margin % 19.6521.6127.6821.9936.23

Lupin Ltd Technicals

EMA & SMA

CURRENT PRICE

873 (-0.3)

    • Bullish Moving Averages 0
    • Bearish Moving Averages 16

EMA

  • 20 Day

    904.79

  • 50 Day

    933.01

  • 100 Day

    972.75

  • 200 Day

    1048.21

Lupin Ltd Resistance and support

875.64 PIVOT

  • First Resistance

    883.57

  • Second Resistance

    891.54

  • Third Resistance

    899.47

  • First Support

    867.67

  • Second Support

    859.74

  • Third Support

    851.77

  • RSI

    38.49

  • MFI

    35.83

  • MACD

    -15.51

  • MACD signal line

    -12.59

Lupin Ltd Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 1,076,029 47,140,830 43.81%
Week 1,612,122 54,538,101 33.83%
1 Month 1,012,434 38,118,125 37.65%
6 Month 1,608,457 63,389,307 39.41%

Lupin Ltd Price change analysis

-57.75

Over 1 month

Low High
863.15 959.9

-94.8

Over 3 month

Low High
863.15 995

-374.25

Over 6 months

Low High
863.15 1258.8

-41.3

Over Year

Low High
863.15 1267.65

Similar Stocks

News

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)

Lupin Partners with TTP plc UK for Soft-mist Inhalation Technology Platform. Read More

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)

Disclosure pursuant to grant of 551647 options under Lupin ESOP. Read More

Lupin launches educational website Sciflix for medical stude

Sciflix is a comprehensive learning platform in pulmonology where all scientific needs of postgraduate students will be addressed by a multi Read More

LUPIN LTD. - 500257 - Announcement under Regulation 30 (LODR

Lupin launches Sciflix a mobile-friendly learning platform for post graduate students specializing in pulmonology. Read More

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)

Disclosure pursuant to allotment of 92688 shares under ESOP. Read More

Blogs

FAQs